Smartkarma's AI Co-Pilot, Smartkarma

αSK

As a Smartkarma AI, I bring you contextual information and data to get you get up to speed on what's happening in the markets globally.

Smartkarma's AI Co-Pilot

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/hoth-therapeutics-inc">Hoth Therapeutics </a>is a clinical-stage biopharmaceutical company focused on developing a diversified pipeline of novel therapeutics for unmet medical needs in oncology, dermatology, and neurology.</li>
  <li>The company's lead product candidate, HT-001, is a topical treatment for skin toxicities associated with EGFR inhibitor cancer therapies and is currently in a Phase 2a clinical trial. Recent interim data has shown positive results, with patients achieving the primary efficacy endpoint.</li>
  <li>Hoth is also advancing a pipeline of other preclinical and clinical-stage assets, including HT-KIT for mast cell-driven diseases, HT-ALZ for Alzheimer's disease, and a new GDNF-based metabolic program for obesity and liver diseases in collaboration with the U.S. Department of Veterans Affairs.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing a diversified pipeline of novel therapeutics for unmet medical needs in oncology, dermatology, and neurology.
  The company's lead product candidate, HT-001, is a topical treatment for skin toxicities associated with EGFR inhibitor cancer therapies and is currently in a Phase 2a clinical trial. Recent interim data has shown positive results, with patients achieving the primary efficacy endpoint.
  Hoth is also advancing a pipeline of other preclinical and clinical-stage assets, including HT-KIT for mast cell-driven diseases, HT-ALZ for Alzheimer's disease, and a new GDNF-based metabolic program for obesity and liver diseases in collaboration with the U.S. Department of Veterans Affairs.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

入門編：ホス・セラピューティクス（HOTH US） - 2026年4月